The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, major cardiac events were observed in the ARCH study, while headaches, arthralgia, and injection site reactions were also observed [89,90].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As of 2021, it has reached Phase III trials, which have shown an increase in bone mineral density and a decrease in vertebral and hip fractures.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ARCH study showed a 48% lower risk of new vertebral fractures in the group that received romosozumab and alendronate than in the alendronate-only group [89].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Osteoporosis: a clinical and pharmacological update
Vidal, M., Thibodaux, R. J., Neira, L. F. V., & Messina, O. D. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4370-1 · Cited by 67
The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women
Sánchez‐Rodríguez, D., Bergmann, P., Body, J., Cavalier, E., Gielen, E., Goemaere, S., Lapauw, B., Laurent, M. R., Rozenberg, S., Honvo, G., et al. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.05.006 · Cited by 66
The Role of Sclerostin in Bone Diseases
Vasiliadis, E. S., Evangelopoulos, D.-S., Kaspiris, A., Benetos, I. S., Vlachos, C., & Pneumaticos, S. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030806 · Cited by 62
Treatment Sequence for Osteoporosis
Cosman, F., Langdahl, B. L., & Leder, B. Z. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.01.014 · Cited by 62
Cardiovascular Safety and Sclerostin Inhibition
Langdahl, B. L., Hofbauer, L. C., & Forfar, J. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab193 · Cited by 64
Sato, M., Inaba, M., Yamada, S., Emoto, M., Ohno, Y., & Tsujimoto, Y. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01253-y · Cited by 61
Identification of an Epigenetic Signature of Osteoporosis in Blood DNA of Postmenopausal Women
Cheishvili, D., Parashar, S., Mahmood, N., Arakelian, A., Kremer, R. B., Goltzman, D., Szyf, M., & Rabbani, S. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3527 · Cited by 61
Bone-organ axes: bidirectional crosstalk
Deng, A.-F., Wang, F., Wang, S., Zhang, Y., Bai, L., & Su, J. (2024) · Military Medical Research · doi:10.1186/s40779-024-00540-9 · Cited by 62
Cosman, F., Lewiecki, E. M., Ebeling, P. R., Hesse, E., Napoli, N., Matsumoto, T., Crittenden, D. B., Rojeski, M., Yang, W., Libanati, C. R., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3996 · Cited by 60
The Inflammatory Contribution of B-Lymphocytes and Neutrophils in Progression to Osteoporosis
Frase, D., Lee, C., Nachiappan, C., Gupta, R., & Akkouch, A. (2023) · Cells · doi:10.3390/cells12131744 · Cited by 59
An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines
Kanis, J. А., Johansson, H., Harvey, N. C., Lorentzon, M., Liu, E., Vandenput, L., & McCloskey, E. V. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05942-2 · Cited by 61
Self-citationRole of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis
Cronin, O., Lanham-New, S. A., Corfe, B. M., Gregson, C. L., Darling, A. L., Ahmadi, K. R., Gibson, P. S., Tobias, J. H., Ward, K. A., Τράκα, Μ., et al. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00924-2 · Cited by 60
Physiological Mineralization during In Vitro Osteogenesis in a Biomimetic Spheroid Culture Model
Koblenzer, M., Weiler, M., Fragoulis, A., Rütten, S., Pufe, T., & Jahr, H. (2022) · Cells · doi:10.3390/cells11172702 · Cited by 63
Chapurlat, R. D., Bui, M., Sornay‐Rendu, E., Zebaze, R. M. D., Delmas, P. D., Liew, D., Lespessailles, É., & Seeman, E. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3924 · Cited by 59
Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs
He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58
van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 60
Role of Sclerostin in Cardiovascular Disease
Golledge, J., & Thanigaimani, S. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317635 · Cited by 58
Leder, B. Z., Mitlak, B., Hu, M., Hattersley, G., & Bockman, R. S. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz162 · Cited by 59
BMP9 Reduces Bone Loss in Ovariectomized Mice by Dual Regulation of Bone Remodeling
Zhou, Y., Yang, Y., Jing, Y., Yuan, T.-J., Sun, L., Tao, B., Liu, J., & Zhao, H. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3957 · Cited by 59
Chandran, M., Mitchell, P., Amphansap, T., Bhadada, S. K., Chadha, M. D., Chan, D., Chung, Y., Ebeling, P. R., Gilchrist, N. L., Khan, A. H., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05742-0 · Cited by 59
Cummings, S. R., & McCulloch, C. E. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05379-z · Cited by 58
Emerging biomimetic nanotechnology in orthopedic diseases: progress, challenges, and opportunities
Zhang, Z., Zhou, J. M., Chuang, L. I. U., Zhang, J., Shibata, Y., Kong, N., Corbo, C., Harris, M. B., & Tao, W. (2022) · Trends in Chemistry · doi:10.1016/j.trechm.2022.02.002 · Cited by 57
Liu, Y., Cao, Y., Zhang, S., Zhang, W., Zhang, B., Tang, Q., Li, Z., & Wu, J. (2018) · Climacteric · doi:10.1080/13697137.2018.1433655 · Cited by 57
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate
Asadipooya, K., & Weinstock, A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312371 · Cited by 56
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture
Bhandari, M., Schemitsch, E. H., Karachalios, T. S., Sancheti, P. K., Poolman, R. W., Caminis, J. N., Daizadeh, N. S., Dent-Acosta, R. E., Egbuna, O. I., Chines, A. A., et al. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.19.01008 · Cited by 56
Kobayakawa, T., Suzuki, T., Nakano, M., Saito, M., Miyazaki, A., Takahashi, J. A., & Nakamura, Y. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101068 · Cited by 55
Shen, Y., Zou, Y., Bie, B., Dong, C., & Lv, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.044 · Cited by 55
Bone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplay
Sheu, A., & White, C. (2024) · Diabetologia · doi:10.1007/s00125-024-06172-x · Cited by 55
The Emerging Role of Osteocytes in Cancer in Bone
Atkinson, E. G., & Delgado‐Calle, J. (2019) · JBMR Plus · doi:10.1002/jbm4.10186 · Cited by 58
Wang, Q., Chen, D., Jin, H., Ye, Z., Wang, C., Chen, K., Kuek, V., Ke Cheng, X. U., Qiu, H., Chen, P., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4025 · Cited by 56
Kaveh, S., Hosseinifard, H., Ghadimi, N., Vojdanian, M., & Aryankhesal, A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-04948-1 · Cited by 55
The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases
Pathak, J. L., Bravenboer, N., & Klein‐Nulend, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00405 · Cited by 57
Baroi, S., Czernik, P. J., Chougule, A., Griffin, P. R., & Lecka‐Czernik, B. (2021) · Bone · doi:10.1016/j.bone.2021.115913 · Cited by 54
Eriksen, E. F., Chapurlat, R. D., Boyce, R. W., Shi, Y., Brown, J. P., Horlait, S., Betah, D., Libanati, C. R., & Chavassieux, P. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4457 · Cited by 54
Turk, J. R., Deaton, A. M., Yin, J., Stolina, M., Felx, M., Boyd, G., Bienvenu, J.-G., Varela, A., Guillot, M., Holdsworth, G., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104697 · Cited by 58
Elbers, L. P. B., Raterman, H. G., & Lems, W. F. (2021) · Drugs · doi:10.1007/s40265-021-01587-x · Cited by 53
Stokar, J., & Szalat, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae173 · Cited by 53
Kendler, D. L., Compston, J. E., CAREY, J. J., Wu, C., Ibrahim, A., & Lewiecki, E. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.07.010 · Cited by 53
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone
Axelsson, K. F., Nilsson, A. G., Wedel, H., Lundh, D., & Lorentzon, M. (2017) · JAMA · doi:10.1001/jama.2017.8040 · Cited by 52
Self-citationMonoclonal antibodies for treating osteoporosis
Faienza, M. F., Chiarito, M., D’Amato, G., Colaianni, G., Colucci, S. C., Grano, M., & Brunetti, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1401607 · Cited by 52
Updates in CKD-Associated Osteoporosis
Khairallah, P., & Nickolas, T. L. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0491-3 · Cited by 52
Rethinking Bone Disease in Kidney Disease
Damasiewicz, M. J., & Nickolas, T. L. (2018) · JBMR Plus · doi:10.1002/jbm4.10117 · Cited by 52
Jin, Y., Lee, J. H., Xu, B., & Cho, M. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2769-8 · Cited by 52
Reginster, J.-Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., & Fitzpatrick, L. A. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04947-2 · Cited by 51
Romosozumab: A Review in Postmenopausal Osteoporosis
Paik, J., & Scott, L. J. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00793-8 · Cited by 51
Management of primary and secondary osteoporosis in children
Sakka, S. D., & Cheung, M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20969262 · Cited by 51
Bone fracture healing: perspectives according to molecular basis
Ruggieri, I. N. C., Cícero, A. M., Issa, J. P. M., & Feldman, S. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01168-0 · Cited by 52
Tominaga, A., Wada, K., Okazaki, K., Nishi, H., Terayama, Y., & Kato, Y. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05925-3 · Cited by 50
Hampson, G., Elder, G. J., Cohen-Solal, M. E., & Abrahamsen, B. (2021) · Endocrine · doi:10.1007/s12020-021-02735-9 · Cited by 50
Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 52
Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin
Rachner, T. D., Hofbauer, L. C., Göbel, A., & Tsourdi, E. A. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0173 · Cited by 50
Geusens, P., Bours, S., Wyers, C. E., & van den Bergh, J. P. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.016 · Cited by 50
McClung, M. R., Bolognese, M., Brown, J. P., Reginster, J., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., & Grauer, A. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05502-0 · Cited by 50
Self-citationCosman, F., Peterson, L. R., Towler, D. A., Mitlak, B., Wang, Y., & Cummings, S. R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa450 · Cited by 50
Wnt signaling: An attractive target for periodontitis treatment
Bao, J., Yang, Y., Xia, M., Sun, W., & Chen, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110935 · Cited by 54
Singla, A. K., Wang, J., Yang, R., Geller, D. S., Loeb, D. M., & Hoang, B. H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_8 · Cited by 51
Management of fracture risk in CKD—traditional and novel approaches
Haarhaus, M. L., Aaltonen, L., Cejka, D., Cozzolino, M. G., de Jongh, R. T., D’Haese, P. C., Evenepoel, P., Lafage‐Proust, M., Mazzaferro, S., McCloskey, E. V., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac230 · Cited by 53
Taha, K. A., Lauper, N., Bauer, D. E., Tsoupras, A., Tessitore, E., Biver, E., & Dominguez, D. E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040930 · Cited by 50
Saito, H., Gasser, A. S., Bolamperti, S., Maeda, M., Matthies, L., Jähn, K., Long, C. L., Schlüter, H., Kwiatkowski, M., Saini, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08778-x · Cited by 51
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations
Pοlyzos, S. A., Anastasilakis, A. D., Efstathiadou, Z. A., Yavropoulou, M. P., & Makras, P. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.02.007 · Cited by 49
Osteoporosis in children and adolescents: how to treat and monitor?
Ciancia, S., Högler, W., Sakkers, R. J. B., Appelman‐Dijkstra, N. M., Boot, A. M., Sas, T., & Renes, J. S. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04743-x · Cited by 52
Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing
Kushchayeva, Y. S., Pestun, I., Kushchayev, S. V., Radzikhovska, N., & Lewiecki, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247477 · Cited by 49
Circulating levels of sclerostin are associated with cardiovascular mortality
Novo‐Rodríguez, C., García-Fontana, B., Castillo, J. D. D. L.-D., Andújar-Vera, F., Ávila-Rubio, V., García‐Fontana, C., Morales, S., Rozas-Moreno, P., & Muñoz‐Torres, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199504 · Cited by 48
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
Toscani, D., Bolzoni, M., Ferretti, M., Palumbo, C., & Giuliani, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02467 · Cited by 49
Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice
Funck‐Brentano, T., Nilsson, K. H., Brommage, R., Henning, P., Lerner, U. H., Koskela, A., Tuukkanen, J., Cohen-Solal, M. E., Movérare‐Skrtic, S., & Ohlsson, C. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0153 · Cited by 50
Combination and sequential treatment in women with postmenopausal osteoporosis
Anastasilakis, A. D., Pοlyzos, S. A., Yavropoulou, M. P., & Makras, P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1717468 · Cited by 47
Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis
Miller, S. A., St. Onge, E. L., & Whalen, K. L. (2021) · Journal of Pharmacy Technology · doi:10.1177/8755122520967632 · Cited by 46
Lewiecki, E. M., Czerwinski, E. J., Recknor, C. P., Strzelecka, A., Valenzuela, G., Lawrence, M., Silverman, S. L., Cardona, J., Nattrass, S., Binkley, N., et al. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4877 · Cited by 46
Adami, G., Pedrollo, E., Rossini, M., Fassio, A., Braga, V., Pasetto, E., Pollastri, F., Benini, C., Viapiana, O., & Gatti, D. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae016 · Cited by 46
Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects
Yao, Y., Kauffmann, F., Maekawa, S., Sarment, L., Sugai, J. V., Schmiedeler, C., Doherty, E. J., Holdsworth, G., Kostenuik, P. J., & Giannobile, W. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-73026-y · Cited by 46
Management of glucocorticoid-induced osteoporosis
Messina, O. D., Vidal, L. F., Vidal, M., Bultink, I. E. M., Raterman, H. G., & Lems, W. F. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01823-0 · Cited by 46
Bone circuitry and interorgan skeletal crosstalk
Zaidi, M., Kim, S.-M., Mathew, M., Korkmaz, F., Sultana, F., Miyashita, S., Gumerova, A. A., Frolinger, T., Moldavski, O., Barak, O., et al. (2023) · eLife · doi:10.7554/elife.83142 · Cited by 45
Saito, T., Mizobuchi, M., Kato, T., Suzuki, T., Fujiwara, Y., Kanamori, N., MAKUUCHI, M., & Honda, H. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-01031-6 · Cited by 45
Bone: Another potential target to treat, prevent and predict diabetes
Liu, D., Mosialou, I., & Liu, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13330 · Cited by 45
The Role of Sclerostin in Bone and Ectopic Calcification
De Maré, A., D’Haese, P. C., & Verhulst, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093199 · Cited by 45
Bisphosphonates and the risk of atypical femur fractures
Black, D. M., Condra, K., Adams, A. L., & Eastell, R. (2021) · Bone · doi:10.1016/j.bone.2021.116297 · Cited by 45
Bisphosphonates pharmacology and use in the treatment of osteoporosis
Diab, D. L., Watts, N. B., & Miller, P. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00074-5 · Cited by 46
Liu, W., Lee, B., Nagamani, S. C. S., Nicol, L. E., Rauch, F., Rush, E. T., Sutton, V. R., & ORWOLL, E. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad035 · Cited by 44
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
Ebina, K., Etani, Y., Noguchi, T., Nakata, K., & Okada, S. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-024-01536-0 · Cited by 44
Addressing the crisis in the treatment of osteoporosis
Roux, C., & Briot, K. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.218 · Cited by 44
Treatment options for glucocorticoid-induced osteoporosis
Chiodini, I., Merlotti, D., Falchetti, A., & Gennari, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1721467 · Cited by 44
Kostenuik, P. J., Binkley, N., & Anderson, P. A. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00793-8 · Cited by 44
Gupta, N., Kanwar, N., Arora, A., Khatri, K., & Kanwal, A. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-06932-5 · Cited by 45
Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis
Rauner, M., & Bözec, A. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01323-9 · Cited by 44
Wnt signaling as target for the treatment of osteoarthritis
Stampella, A., Monteagudo, S., & Lories, R. J. U. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.03.004 · Cited by 43
Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
Tonk, C. H., Shoushrah, S. H., Babczyk, P., Khaldi-Hansen, B. E., Schulze, M., Herten, M., & Tobiasch, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031393 · Cited by 44
Imminent fracture risk assessments in the UK FLS setting: implications and challenges
Pinedo‐Villanueva, R., Charokopou, M., Toth, E., Donnelly, K., Cooper, C. C., Prieto‐Alhambra, D., Libanati, C. R., & Javaid, M. K. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0569-2 · Cited by 44
Recommendations for the optimal use of bone forming agents in osteoporosis
Veronese, N., Briot, K., Guañabens, N., Albergaria, B. H., Alokail, M. S., Al‐Daghri, N. M., Bemden, A. B., Bruyère, O., Burlet, N., Cooper, C. C., et al. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02826-3 · Cited by 42
Self-citationBalancing benefits and risks in the era of biologics
Adami, G., Saag, K. G., Chapurlat, R. D., Guañabens, N., Haugeberg, G., Lems, W. F., Matijević, R., Peel, N. F. A., Poddubnyy, D., & Geusens, P. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19883973 · Cited by 42
Self-citationChotiyarnwong, P., McCloskey, E. V., Harvey, N. C., Lorentzon, M., Prieto‐Alhambra, D., Abrahamsen, B., Adachi, J. D., Borgström, F., Bruyère, O., CAREY, J. J., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01117-6 · Cited by 44
Self-citationGlendenning, P., Chubb, S. A. P., & Vasikaran, S. D. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.009 · Cited by 44
Polypharmacy in Osteoporosis Treatment
McConnell, M., & Shieh, A. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.05.011 · Cited by 41
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges
O’Brien, S., Chidiac, R., & Angers, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.008 · Cited by 42
Recent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 42
Li, X., Peng, B., Zhu, X., Wang, P., Sun, K., Lei, X., He, H., Tian, Y., Mo, S., Zhang, R., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28916 · Cited by 41
Role of bone-forming agents in the management of osteoporosis
McClung, M. R. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01708-8 · Cited by 42
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
Cosman, F., & Dempster, D. W. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00663-1 · Cited by 41
PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus
Marino, S., & Bellido, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01014-7 · Cited by 42
Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants
Yu, S. H., Hao, J., Fretwurst, T., Liu, M., Kostenuik, P. J., Giannobile, W. V., & Jin, Q. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2018.0013 · Cited by 41
Sclerostin: From Molecule to Clinical Biomarker
Omran, A. S., Atanasova, D., Landgren, F., & Magnusson, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094751 · Cited by 44
Metadata
- Authors
- Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
- Affiliations
- Inserm (FR)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2754720807
- Cited by
- 1,544
- References
- 31
- Citations by year
- 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
- FWCI
- 123.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Teva Pharmaceutical Industries
- Radius Health
- Medac
- Chugai Pharmaceutical
- Amgen Canada
- UCB Pharma
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
- MeSH terms
- Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
